Anti-asthma drug Xolair is on a roll

When you're hot, you're hot. The Novartis/Genentech allergy drug Xolair got a big thumbs-up in yesterday's new asthma treatment guidelines. Today, the Brits say they want their patients with severe asthma to get Xolair, too.

The National Institute for Health and Clinical Excellence (NICE), which decides whether the National Health Service should pay for individual drugs, recommended Xolair for use in patients whose asthma is so severe, it has confined them to hospital at least once within the past year. NICE says the recommendation isn't final, though, because it's still appraising the drug--but it is the details that are likely to change, not the overall feeling that Xolair's hot stuff.

- here's the AFX report

Virtual Clinical Trials Summit

Virtual Clinical Trials Summit: The Premier Educational Event Focused on Decentralized Clinical Trials

In this virtual environment, we will look at current and future trends for ongoing virtual trials, diving into the many ways companies can improve patient engagement and trial behavior to enhance retention with a focus on emerging technology and harmonized data access across the clinical trial system.